Three tests come up repeatedly in the functional medicine and integrative health world when SIBO is suspected: the lactulose or glucose breath test, the GI-MAP stool DNA test, and the Organic Acids Test (OAT). Patients often assume that more testing is always better and may spend hundreds or thousands of dollars running all three simultaneously, sometimes arriving at conflicting results that create more confusion than clarity. The truth is that these tests measure completely different things — and only one of them, the breath test, actually measures what directly defines SIBO. This article explains exactly what each test measures, what it can and cannot tell you about small intestinal bacterial overgrowth, and how to build a rational, cost-effective diagnostic strategy.
The Breath Test: The SIBO Diagnostic Standard
The lactulose or glucose breath test is the most widely used non-invasive diagnostic tool for SIBO and is the test that directly addresses the defining feature of the condition: the presence of excess bacteria in the small intestine producing fermentation gases. The mechanism is straightforward: you drink a measured dose of a carbohydrate substrate (lactulose or glucose), and the test measures hydrogen and methane gas in your exhaled breath over 90-180 minutes at timed intervals. These gases are produced by bacteria when they ferment carbohydrates — something that should not happen significantly in the small intestine if bacterial populations are at normal levels. A positive test indicates that fermentable carbohydrates are being metabolized by bacteria before they reach the colon, which means too many bacteria are present upstream. The North American Consensus criteria define a positive hydrogen breath test as a rise of 20 ppm or more above baseline within 90 minutes on a lactulose test, or any rise of 20 ppm on a glucose test. For methane, positivity is defined as any reading of 10 ppm or higher at any point during the test. Three-gas breath tests (TrioSmart from Gemelli Biotech) also measure hydrogen sulfide. Breath testing has several practical advantages: it is widely available (many gastroenterology practices and specialty labs offer it), it can be done at home with a mail-in kit, it tests for the specific gas types that determine your SIBO type, and it provides quantitative data (gas levels in parts per million) that can be used to track treatment response. Its limitations are equally important to understand: the test has meaningful false positive and false negative rates. False positives can occur when colonic bacteria ferment the substrate faster than usual (rapid transit can produce an early gas rise that mimics SIBO). False negatives occur when organisms don't produce enough detectable gas, when a patient has had recent antibiotics that suppressed gas production, or when hydrogen sulfide is the primary gas (missed by two-gas tests). The preparation protocol — a specific low-FODMAP diet for 24 hours before testing, followed by an overnight fast — must be followed precisely to minimize false results.
ℹ️The gold standard for SIBO diagnosis is not the breath test — it is direct aspiration and culture of small intestinal fluid via endoscopy, which allows direct counting of bacterial colonies. A count above 10^3 colony-forming units per milliliter of jejunal aspirate is the traditional diagnostic threshold. This procedure is rarely performed outside of research settings due to its invasiveness, cost, and technical requirements. The breath test is the practical standard precisely because it is non-invasive and accessible.
The GI-MAP: What It Measures and What It Misses
The GI-MAP (Gastrointestinal Microbial Assay Plus) is a stool DNA test offered by Diagnostic Solutions Laboratory. It uses quantitative PCR (polymerase chain reaction) to detect the DNA of specific pathogens, commensal bacteria, parasites, and fungi in a stool sample. It is a sophisticated and detailed test that provides information on organisms including H. pylori, Campylobacter, E. coli variants, Clostridium difficile, Giardia, Cryptosporidium, a range of fungi including Candida species, and various markers of gut inflammation and function (including calprotectin, zonulin, secretory IgA, and anti-gliadin antibodies). Here is what the GI-MAP cannot tell you about SIBO: it analyzes stool, which comes from the colon. Small intestinal bacterial overgrowth, by definition, occurs in the small intestine — and the microbiome of the small intestine is completely different from the microbiome of the colon. The organisms that cause SIBO are generally not present in stool at detectable levels, or if they are, their presence in stool does not indicate where they are in the GI tract. A stool test cannot diagnose SIBO. This is not a criticism of the GI-MAP as a test — it is an excellent tool for what it was designed to do, which is characterize the colonic microbiome and detect specific pathogens. But it should not be used as a SIBO diagnostic tool, and a negative GI-MAP does not rule out SIBO, nor does any finding on a GI-MAP confirm SIBO. The GI-MAP is most useful for identifying specific pathogens (H. pylori is a particularly important finding that has direct treatment implications), characterizing colonic dysbiosis, detecting parasitic infections that can mimic SIBO symptoms, and assessing markers of gut barrier function and inflammation. These findings can complement a SIBO breath test by identifying co-existing issues that may perpetuate symptoms.
The Organic Acids Test: Metabolites as Clues
The Organic Acids Test (OAT) is a urine test that measures hundreds of metabolic byproducts produced by human cells, bacteria, and fungi. It is offered by several functional medicine laboratories including Great Plains Laboratory (now Mosaic Diagnostics) and Genova Diagnostics. The OAT's connection to SIBO comes from the fact that certain bacteria and fungi produce specific organic acid metabolites that can be detected in urine — theoretically indicating their presence in the gut. The most commonly cited SIBO-relevant markers on the OAT include D-arabinitol and L-arabinitol (associated with Candida and other fungal overgrowth), and certain byproducts of bacterial fermentation like phenylpropionate and para-hydroxyphenyl derivatives that may indicate bacterial protein fermentation. The connection between OAT results and SIBO specifically is tenuous and not validated in clinical studies in the same way as breath testing. Elevated bacterial fermentation markers on an OAT suggest some degree of intestinal dysbiosis, but they cannot localize the problem to the small intestine versus the colon, cannot specify the organisms involved, and have not been validated against the gold standard of jejunal aspirate culture. The OAT provides potentially useful information about overall metabolic dysbiosis, yeast overgrowth, mitochondrial function, neurotransmitter metabolism, and nutrient sufficiency — making it a broad functional medicine screen rather than a targeted SIBO diagnostic tool. Practitioners who use it for SIBO typically do so as part of a broader functional medicine workup, not as a primary SIBO test.
What each test measures and its SIBO relevance at a glance:
- Lactulose/Glucose Breath Test — measures hydrogen and methane gas in exhaled breath after substrate ingestion; directly detects small intestinal bacterial fermentation; the primary diagnostic tool for SIBO; cost ~$150-400
- TrioSmart Three-Gas Breath Test — adds hydrogen sulfide measurement to standard breath test; detects ISO (intestinal sulfide overgrowth) that standard tests miss; cost ~$225-350
- GI-MAP Stool DNA Test — detects specific organisms in stool via qPCR; excellent for pathogens, H. pylori, parasites, and colonic dysbiosis; cannot diagnose SIBO (wrong location); cost ~$350-500
- Organic Acids Test (OAT) — measures metabolites in urine; may indicate fungal overgrowth and general dysbiosis; not validated for SIBO diagnosis; useful as broad functional medicine screen; cost ~$250-400
- Jejunal aspirate culture — direct culture of small intestinal fluid; true gold standard for SIBO; rarely performed outside research; requires endoscopy
⚠️A negative GI-MAP or OAT does not rule out SIBO. These tests cannot detect small intestinal bacterial overgrowth because they analyze the wrong anatomical compartment (stool) or indirect metabolic signals (urine). If SIBO is clinically suspected based on your symptoms and history, a breath test is required for diagnosis — not a stool or urine test.
Accuracy, False Positives, and Limitations
Breath testing sensitivity and specificity for SIBO varies considerably across studies, partly because the test methodology (substrate type, gas sampling intervals, positivity criteria) is not standardized across labs. Using the North American Consensus criteria, lactulose breath testing has been estimated to have a sensitivity of approximately 42-68% and a specificity of 44-64% for SIBO diagnosis compared to jejunal aspirate — numbers that reflect meaningful false positive and false negative rates. Glucose breath testing tends to have higher specificity (fewer false positives) but lower sensitivity (more false negatives), because glucose is absorbed in the proximal small intestine and may not reach bacteria located more distally. The clinical takeaway is that breath testing is imperfect, and a negative result does not definitively rule out SIBO in a patient with compelling symptoms. Many SIBO specialists use clinical presentation, symptom response to treatment, and breath testing together rather than relying on any single result. A patient with classic SIBO symptoms who tests negative on breath testing but responds dramatically to rifaximin has effectively confirmed the diagnosis through treatment response — a strategy sometimes called 'empiric treatment.' For GI-MAP and OAT, accuracy in the context of SIBO is essentially not applicable — these tests are measuring different things and cannot be assigned SIBO-specific sensitivity and specificity values.
Recommended Testing Strategy
A rational, cost-effective SIBO diagnostic strategy starts with the breath test because it is the only available non-invasive tool that directly measures small intestinal bacterial activity. For most patients with suspected SIBO, the sequence should be: first, a three-gas breath test (lactulose or glucose substrate, measuring hydrogen, methane, and hydrogen sulfide) after proper preparation; and second, H. pylori testing (either via GI-MAP, stool antigen test, or urea breath test) because H. pylori infection is present in a significant proportion of SIBO patients and impairs gastric acid production, which is a major SIBO predisposing factor. A GI-MAP makes sense as an add-on test when symptoms include features that suggest parasitic infection (travel history, exposure to contaminated water), when there are findings suggesting inflammatory bowel disease, or when SIBO treatment has been partially successful and the provider suspects co-existing colonic dysbiosis or pathogen involvement. An OAT is reasonable as part of a broad functional medicine evaluation — particularly when fatigue, cognitive symptoms, or suspected yeast overgrowth are prominent — but should not be the primary or sole diagnostic tool for suspected SIBO. The most important principle is to match the test to the clinical question. If the question is 'do I have SIBO?', the breath test is the answer. If the question is 'what else might be wrong with my gut?' the GI-MAP and OAT can contribute meaningful additional information.
💡Track your symptoms for 2-4 weeks before your breath test using a SIBO tracking app. Detailed symptom logs — noting timing of bloating relative to meals, bowel patterns, food triggers, and gas type — give your provider invaluable context for interpreting your breath test result and designing your treatment protocol. A breath test result without clinical context is much harder to act on.
**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.